A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Camptothecin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 27 Mar 2012 Company (Cerulean Pharma) added as trial sponsor as reported by ClinicalTrials.gov.
- 27 Mar 2012 Company (Cerulean Pharma) added as trial sponsor as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.